Events & Presentations

Featured Webinars

SELLAS Life Science Phase 3 REGAL Study Update
Galinpepimut-S Update Call
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer
Shareholder Update Call - April 6, 2022
SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients RelapsedRefractory to Venetoclax in Ongoing Phase 1 Study
University of Pennsylvania Study Shows CD4 As Key Driver in Success of CAR-T Therapies to Cure Leukemia
SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer
SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China

Investor Presentation

Archived Events & Presentations